PMID- 1731054
OWN - NLM
STAT- MEDLINE
DCOM- 19920218
LR  - 20181130
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 260
IP  - 1
DP  - 1992 Jan
TI  - Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 
      4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle 
      reflexes in rats.
PG  - 78-89
AB  - The substituted amphetamines 4-chloroamphetamine (PCA), 
      3,4-methylenedioxymethamphetamine (MDMA) and fenfluramine (FEN) share the common 
      neurochemical action of acutely releasing central serotonin (5-HT), and yet their 
      behavioral effects are quite different. The present study evaluated the effects 
      of these compounds on acoustic and tactile startle reflexes. PCA and MDMA were 
      qualitatively similar in producing dose-related increases in acoustic and tactile 
      startle reflexes that were slow in onset, but sustained throughout the 3.5-hr 
      test session. Changes in motor activity did not account for the observed 
      excitation of startle. In marked contrast to MDMA and PCA, FEN did not alter 
      tactile startle and tended to depress acoustic startle. The excitatory effect of 
      20 mg/kg of MDMA was prevented by the 5-HT uptake blockers MDL 27,777A and 
      fluoxetine. MDMA excitation was not affected by a dose of the dopamine antagonist 
      haloperidol that attenuated the startle-enhancing effect of d-amphetamine. MDMA 
      excitation was greatly attenuated by a general depletion of central 5-HT produced 
      by prior intraventricular injection of the 5-HT neurotoxin 
      5,7-dihydroxytryptamine. PCA and MDMA excitations of startle were attenuated in 
      rats specifically depleted of spinal 5-HT or in rats with radio frequency lesions 
      of the dorsal raphe nucleus. Thus, PCA and MDMA have similar prolonged excitatory 
      effects on startle reflexes that are mediated by ascending (dorsal raphe) and 
      descending (spinal) pathways, whereas FEN differs in its lack of excitation of 
      startle. Differences in the neurochemical properties of these compounds or their 
      patterns of 5-HT release may underlie their different behavioral profiles.
FAU - Kehne, J H
AU  - Kehne JH
AD  - Marion Merrell Dow Research Institute, Cincinnati, Ohio.
FAU - McCloskey, T C
AU  - McCloskey TC
FAU - Taylor, V L
AU  - Taylor VL
FAU - Black, C K
AU  - Black CK
FAU - Fadayel, G M
AU  - Fadayel GM
FAU - Schmidt, C J
AU  - Schmidt CJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Indenes)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 130835-44-8 (MDL 27777)
RN  - 2DS058H2CF (Fenfluramine)
RN  - 31363-74-3 (5,7-Dihydroxytryptamine)
RN  - 333DO1RDJY (Serotonin)
RN  - 6384-92-5 (N-Methylaspartate)
RN  - 64-12-0 (p-Chloroamphetamine)
SB  - IM
MH  - 5,7-Dihydroxytryptamine/pharmacology
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Fenfluramine/*pharmacology
MH  - Fluoxetine/pharmacology
MH  - Indenes/pharmacology
MH  - Male
MH  - N-Methylaspartate/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Reflex, Acoustic/*drug effects
MH  - Reflex, Startle/*drug effects
MH  - Serotonin/*metabolism/physiology
MH  - Touch/drug effects
MH  - p-Chloroamphetamine/*pharmacology
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 1992 Jan;260(1):78-89.